ELAB vs RUN · rev $1.7M vs P/E 6.0, rev $2.04B
Elevai Labs, Inc. Common Stock (ELAB) versus Sunrun Inc (RUN) — a side-by-side from cached financials, not a winner call.
Elevai Labs, Inc. Common Stock (ELAB) is a biotechnology company listed on NASDAQ.
Sunrun Inc (RUN) is a solar company listed on NASDAQ.
Latest reported ELAB revenue for 2023-12-31 was $1.7M. Net income was -$4.3M. Revenue was up 123.5% from 2022-12-31 to 2023-12-31. ELAB currently screens at market cap $6.5M.
Latest reported RUN revenue for 2024-12-31 was $2.04B. Net income was -$4.36B. Revenue was down 9.8% from 2023-12-31 to 2024-12-31. RUN currently screens at market cap $3.05B and trailing P/E 6.0.
ELAB currently screens at market cap $6.5M. RUN currently screens at market cap $3.05B and trailing P/E 6.0.
Not investment advice. Open the ELAB and RUN stock pages for the full models.
Not investment advice.